Nuo Therapeutics, Inc. (AURX) — 10-K Filings
All 10-K filings from Nuo Therapeutics, Inc.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (3)
-
Nuo Therapeutics' Revenue Jumps 121% on Aurix Adoption, Smith+Nephew Deal
— Mar 30, 2026 Risk: high
Nuo Therapeutics, Inc. (AURX) reported significant revenue growth in its 2025 fiscal year, with product revenues increasing from approximately $1.4 million in 2 -
Nuo Therapeutics Files 2024 10-K, Notes March 2025 Agreement
— Apr 1, 2025 Risk: medium
Nuo Therapeutics, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly known as CytomediX Inc., is based in Houston, TX. A si -
Nuo Therapeutics, Inc. Files 2023 Annual Report on Form 10-K
— Apr 19, 2024 Risk: low
Nuo Therapeutics, Inc. (AURX) filed a Annual Report (10-K) with the SEC on April 19, 2024. Nuo Therapeutics, Inc. filed its 2023 Form 10-K on April 19, 2024. Th
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX